Allergens of the entomopathogenic fungus Beauveria bassiana
© Westwood et al; licensee BioMed Central Ltd. 2005
Received: 16 November 2004
Accepted: 11 January 2005
Published: 11 January 2005
Beauveria bassiana is an important entomopathogenic fungus currently under development as a bio-control agent for a variety of insect pests. Although reported to be non-toxic to vertebrates, the potential allergenicity of Beauveria species has not been widely studied.
IgE-reactivity studies were performed using sera from patients displaying mould hypersensitivity by immunoblot and immunoblot inhibition. Skin reactivity to B. bassiana extracts was measured using intradermal skin testing.
Immunoblots of fungal extracts with pooled as well as individual sera showed a distribution of IgE reactive proteins present in B. bassiana crude extracts. Proteinase K digestion of extracts resulted in loss of IgE reactive epitopes, whereas EndoH and PNGaseF (glycosidase) treatments resulted in minor changes in IgE reactive banding patterns as determined by Western blots. Immunoblot inhibitions experiments showed complete loss of IgE-binding using self protein, and partial inhibition using extracts from common allergenic fungi including; Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, Candida albicans, Epicoccum purpurascens, and Penicillium notatum. Several proteins including a strongly reactive band with an approximate molecular mass of 35 kDa was uninhibited by any of the tested extracts, and may represent B. bassiana specific allergens. Intradermal skin testing confirmed the in vitro results, demonstrating allergenic reactions in a number of individuals, including those who have had occupational exposure to B. bassiana.
Beauveria bassiana possesses numerous IgE reactive proteins, some of which are cross-reactive among allergens from other fungi. A strongly reactive potential B. bassiana specific allergen (35 kDa) was identified. Intradermal skin testing confirmed the allergenic potential of B. bassiana.
Microorganisms are currently under intensive study for use as biopesticides [1–3]. Several fungal species including Metarhizium anisopliae, Verticillium lecanii, and Beauveria bassiana are being used as biocontrol agents for a number of crop, livestock, and human nuisance pests [4–7]. Strains of B. bassiana have been licensed for commercial use against whiteflies, aphids, thrips, and numerous other insect and arthropod pests. B. bassiana fungal formulations are being spread onto a range of vegetables, melons, tree fruits and nuts, as well as organic crops. As alternatives to chemical pesticides these agents are natural occurring and are considered to be non-pathogenic to humans, although a few cases of B. bassiana mediated tissue infections have been reported [8, 9].
Airborne mold spores are widespread, and many have been identified as inhalant allergens eliciting type I hypersensitive reactions in atopic individuals [10–14]. Common allergenic moulds include the anamorphs of ascomycetes and constitute many species within the Alternaria, Aspergillus, and Cladosporium genera [15–19]. The genes encoding for numerous fungal allergens have been isolated, and their protein products expressed and characterized. Purified fungal allergens have been shown to be bound by human IgEs and to elicit allergic reactions in atopic individuals using skin prick tests. Patients with mould allergies often display IgE-mediated responses to multiple fungi, a phenomenon typically thought to result from the presence of common cross-reactive allergen(s) [15, 20–22], although parallel independent sensitization to multiple fungal allergens can also occur. In this regards, identification of genus and/or species specific allergens would provide useful tools in differentiating allergic reactions due to primary sensitization and those mediated by cross-reactive epitopes.
In the present study, we demonstrate Beauveria bassiana crude extracts contain numerous allergens capable of being recognized by human serum IgEs. The allergens were proteinaceous in nature, and immunoblot inhibition experiments revealed the presence of shared epitopes between Beauveria and several other common fungal moulds. Potential Beauveria-specific allergens were also identified, including a strongly reactive ~35-kDa protein band. Intradermal skin testing using B. bassiana extracts resulted in allergenic reactions in several individuals, including some who have had occupational exposure to the fungus.
Strains and cultures
Beauveria bassiana (ATCC 90517) was grown on Sabouraud dextrose + 0.5–1% yeast extract or Potato dextrose (PD) media on either agar plates or in liquid broth. Plates were incubated at 26°C for 10–12 days and conidia were harvested by flooding the plate with sterile dH2O containing 0.01% Tween-20. Liquid cultures were inoculated with conidia harvested from plates at 0.5–1 × 105 conidia/ml.
Alternaria alternata, Aspergillus fumigatus, Candida albicans, Cladosporium herbarum, Epicoccum purpurascens, and Penicillium notatum were acquired from Greer Laboratories inc., (Lenoir, NC). Extracts were resuspended in TE (40 mM Tris-HCl, pH 8.0, 1 mM EDTA) to a final concentration of 2 mg/ml. Beauveria bassiana was grown in Sabouraud's broth containing 1% yeast extract with aeration at 25°C for 3–5 d. Cellular mass was harvested by centrifugation (10,000 × g, 10 min) and freeze-dried. Cells were resuspended in TE containing 0.1% phenylmethylsulfonyl fluoride (PMSF) and homogenized using a bead-beater apparatus.
Crude extracts of B. bassiana were subjected to three successive precipitations before use in Western blots.
Homogenized B. bassiana extracts (50 ml) were mixed with 8 × volume (400 ml) of acetone (kept at -20°C), with rapid stirring, and incubated overnight at -20°C. The precipitate was collected by centrifugation (30 min, 4000 × g), and the pellet was air dried (10 min) before being resuspended in TE containing 0.1% PMSF.
Streptomycin precipitation (removal of DNA)
Streptomycin sulfate (5 ml of 10% solution) was added dropwise to resuspended acetone precipitated extracts (40 ml) at 4°C with rapid stirring. Samples were incubated for an additional 30 min on ice before being centrifuged (15 min, 10,000 × g) in order to remove the precipitate. Proteins in the resultant supernatant were precipitated using ammonium sulfate.
The proteins present in the streptomycin sulfate treated supernatant were precipitated using ammonium sulfate (75%, final concentration). Saturated ammonium sulfate (120 ml) was added dropwise to the Beauveria extract (40 ml) at 4°C with rapid stirring. The solution was allowed to stir overnight at 4°C and precipitated proteins were harvested by centrifugation (30 min, 100,000 × g). The protein pellet was resuspended in TE containing 0.1% PMSF (40 ml) and extensively dialyzed against the same buffer before use.
SDS-Polyacrylamide gel electrophoresis (PAGE)
Protein samples (30–40 μg) were analyzed by sodium-dodecyl-sulphate-polyacrylaminde gel electrophoresis (SDS-PAGE, 10% Bis-tris gel, Invitrogen, Carlsbad, CA) using standard protocols. Gels were stained with Gelcode blue stain reagent (Pierce, Rockford, IL) and subsequently de-stained with dH20.
Protein samples were separated under reducing conditions using 10% Bis-tris polyacrylamide gels (Invitrogen Mops system) and transferred to polyvinylidene-fluoride (PVDF) membranes (Invitrogen) as described. Immunoblot experiments were performed using individual and pooled human sera as the primary antibody solution as indicated. Typically, sera were diluted 1:5 with Tris-HCl buffered saline (TBS) containing 5% dry milk + 0.1% Tween-20. IgE-specific reactivity was visualized using a horseradish peroxidase (HRP) conjugated goat anti-human IgE (polyclonal) secondary antibody (BioSource International, Los Angeles, CA). Membranes were washed with TBS containing 0.1% Tween-20 and bands were visualized using the Immuno-Star HRP detection system (Biorad, Hercules, CA).
The ammonium sulfate fraction of B. bassiana crude extracts was treated with Proteinase K (ICN-Biomed, Aurora, Oh) following standard protocols. Typically, samples (36 μl) were incubated with 4 μl Proteinase K solution (10 mg/ml in 50 mM Tris-HCl, pH 7.5) for 2 hr at 37°C before analysis. Samples were also treated with endoglycosidase-H (EndoH, New England Biolabs, Beverly, MA) and peptide: N-Glycosidase F (PNGaseF, New England Biolabs) according to the manufacturer's recommendations. For EndoH and PNGaseF treatments, samples (36 μl) were denatured in 4 μl 10 × denaturing buffer (0.5% SDS, 1% β-mercaptoethanol) at 100°C for 10 min prior to the addition of the EndoH (5 μl of 10 × G5 Reaction Buffer, 50 mM sodium citrate, pH 5.5) and PNGaseF reaction buffers (50 mM sodium phosphate pH 7.5) and enzymes (5 μl), respectively. Reactions were incubated at 37°C for 2 h before being analyzed by SDS-PAGE and Western blotting.
IgE binding to B. bassiana proteins were competed with proteins of other fungal extracts. SDS-PAGE resolved B. bassiana proteins were electroblotted to PVDF membranes as described above. Membranes were blocked with TBS containing 5% dry milk + 0.1% Tween-20 and strips were incubated with pooled human sera (1:5 v/v in same buffer) containing 100–500 μg of the indicated fungal crude protein extract.
Skin sensitivity profiles to fungal extracts
Patients were tested with 9 common fungal extracts for allergy diagnosis using a skin prick assay. The following extracts were obtained from ALA-Abello (Round Rock, TX); Alternaria tenius, Aspergillus fumigatus, Cephalosporium (Acremonium strictum), Curvularia spp. Bipolaris, Epicoccum nigram, Fusarium spp., Helminthosporium sativum, Hormodendrum horde, Penicillium (mixed, P. chrysogenum and P. notatum). Extracts were tested using a 1:10 dilution of the 20,000 PNU/ml stock solution, and skin sensitivity was recorded on a relative scale from 0–4 reflecting the size of induration or weal (4 representing the highest reactivity) and using histamine (0.1 mg/ml) reaction scored as a 3 if no interference was present.
Intradermal skin testing
B. bassiana crude extracts were prepared as described above but were extensively dialyzed against 0.15 N NaCl and filtered through a 0.22 μm filter before use. Subjects were given intradermal injections of 0.1 ml crude extract ranging in concentration from 0.01–1 mg/ml. Control injections included saline and histamine (0.1 mg/ml). Allergenic reactions were allowed to develop for 15–30 min before the height and width of the reactions were recorded.
Identification of IgE reactive bands
Allergic profile of patients A–G, obtained by skin prick testing.
Individual Skin Reactivity to Fungal Extracts*
Immunoprint Analysis of B. bassiana: Reactivity with Individual Sera
Intradermal Skin Testing
Intradermal skin test results using B. bassiana extract
Histamine control1 (0.1 mg/ml)
B. bassiana Extract (1 mg/ml)
7 × 6
12 × 16
8 × 8
12 × 13
20 × 15
55 × 50
13 × 12
14 × 13
11 × 10
16 × 33
13 × 14
26 × 28
15 × 16
36 × 44
10 × 12
10 × 12
16 × 14
38 × 58
10 × 11
21 × 17
21 × 16
39 × 59
9 × 8
18 × 21
15 × 17
44 × 45
5 × 4
5 × 4
15 × 14
36 × 38
9 × 12
10 × 13
15 × 15
55 × 38
4 × 4
11 × 13
20 × 19
38 × 43
4 × 4
4 × 4
Cross-reactivity among different fungi
In order to determine the extent of cross-reactivity of B. bassiana allergens with other fungi, immunoblot inhibition experiments were performed. Identical concentrations of B. bassiana crude extract (40 μg) were resolved by SDS-PAGE, blotted to PVDF membranes, and lanes were cut into separate strips. Each strip was treated with a 1:5 dilution pooled sera (serum mix-II) as the primary antibody supplemented with concentrations of fungal crude extracts as described in the Materials and Methods. Fig. 3 shows Western blots in which the binding of human IgEs to allergens present in B. bassiana extracts were competed with: excess crude extracts from Alternaria alternata (Fig 3, lanes 3, 4), Aspergillus fumigatus (lanes 5, 6), Cladosporium herbarum (lanes 7), Epicoccum purpurascens (Lane 8), Penicillium notatum (lane 9), and Candida albicans (lane 10). There was complete loss of all signals using 2-fold excess B. bassiana extract as the competitor (data not shown). These data indicate that while Beauveria possess many epitopes in common with several other fungi, notably Alternaria and Penicillium, a 35-kDa major reactive band was not inhibited by any extract tested.
Although it is well known that fungi are important triggers of respiratory allergies, the potential allergenicity of entomopathogenic fungi used in biocontrol has largely been untested. Aerobiological surveys of conidial fungi and skin sensitivity tests to fungal extracts performed in the 1980s in the Netherlands revealed that although Beauveria could barely be detected in airborne samples, and represented less than 0.1% of the airborne fungal "flora", the incidence of allergic skin test reaction to Beauveria was the highest of all fungal species tested [10, 23, 24]. In rural areas, the use of fungi in agricultural pest management practices can greatly increase the potential for human exposure to these agents. Likewise, in urban settings, the commercialization of fungal products for household use may potentiate a much wider problem since indoor air concentrations of the moulds can greatly increase. For these reasons, an examination of the allergenic potential of Beauveria bassiana is imperative.
The present study demonstrated the allergenic potential of B. bassiana directly by intradermal skin testing of individuals and in vitro by revealing the presence of serum IgEs capable of binding allergens present in fungal crude extracts. Over 20 different IgE binding proteins were observed using Western blots probed with sera from patients displaying mould allergies. Results using individual sera revealed a wide variation in IgE-binding proteins between sera, although several common bands, including a protein with an apparent molecular mass of 35 kDa were visible among the sera of several patients.
Our in vitro observations were confirmed by intradermal skin testing on individuals using B. bassiana extracts. While the testing sample population was small, these results indicated that our extracts were able to elicit allergic reactions in individuals, including some that have had occupational exposure to the fungus. Concentrations of ~1 mg/ml of B. bassiana extracts were required to elicit indurations equivalent to 0.1 mg/ml histamine in most individuals, indicating the possibility of potent allergens in the Beauveria extract. Interestingly, not all individuals specifically exposed to B. bassiana displayed allergic reactions and individuals J, K, and M (who did display mild allergic reactions, Table 2) did not react to the 35 KDa protein based upon Western blotting results (Fig. 2). We do not, however, have any quantifiable index of exposure for the individuals in our sample and any interpretations should be made with some caution.
Numerous studies have revealed the presence of cross-reactive proteins among fungal species between genera [15, 20–22, 25–27]. In our experiments, (excess) crude extract from a test organism was added during the primary antibody (human sera) incubation. Common or shared epitopes between B. bassiana and the test fungus would result in a loss of signal due to competition for reactive IgEs. However, IgEs reactive to Beauveria-specific allergens would not be affected, resulting in no change in the corresponding reactive bands on a Western blot. Loss of a signal would indicate that a homolog or shared epitope (IgE-reactive) exists between the two fungal species, implying that primary sensitization by one organism can result in an allergic reaction when exposed to the homologous allergen of another organism. Competitive immunoblot inhibition experiments revealed significant epitope homology between B. bassiana and several clinically important fungi responsible for IgE-mediated allergic reactions in atopic individuals. Thus, an allergic reaction to Beauveria exposure may arise in patients sensitized to other fungi. Extracts from A. alternata and E. purpurascens almost completely competed with allergens present in the B. bassiana extract with the notable exception of the ~35 kDa allergen. Competition experiments using A. fumigatus, C. herbarum, C. albicans, and P. notatum extracts also indicated the presence of many shared epitopes, although distinct (non-competed) IgE-binding B. bassiana proteins of 35 kDa, 64 kDa, and >200 kDa molecular mass were detectable. These proteins, particularly the 35 kDa allergens may represent B. bassiana specific allergens. Experiments are underway to characterize the 35 kDa allergen, which may lead to a diagnostic assay for B. bassiana sensitization. Finally, our analysis of potential B. bassiana allergens was limited to cell extracts grown under specific conditions and did not include the culture filtrate. Extracellular proteases, an important class of fungal proteins that can elicit allergenic reactions, have been characterized from a number of fungal species [28–31], and are likely to be present in B. bassiana. A careful examination of culture growth conditions is also warranted in order to provide a standardized reagent for testing purposes.
Although Beauveria holds promise as an arthropod biological control agent, there have been few reports on the allergenic potential of these organisms. Identification of B. bassiana specific allergens can lead diagnostic methods for determining sensitization to this organism and may provide a rational basis for allergen attenuation in order to yield safer biocontrol products. The observed cross-reactivity among proteins of B. bassiana and the fungi tested, highlight the importance of considering the possibility that multiple fungal sensitivity can occur due to exposure to a single fungus. Further testing should be performed to determine the scope, severity, and range of allergenic reactions to B. bassiana.
We would like to thank Ruby Teng and Moya Chin for technical assistance. This paper is Florida Agricultural Experimental Station Journal series number R-10187.
- McCoy CW: Entomogenous fungi as microbial pestidides. New Directions in Biological Control. Edited by: Baker RR and Dunn PE. 1990, 139-159. New York, NY, A.R. Liss.
- Leathers TD, Gupta SC, Alexander NJ: Mycopesticides: status, challenges, and potential. Journal of Industrial Microbiology. 1993, 12: 69-75.View Article
- Shah PA, Pell JK: Entomopathogenic fungi as biological control agents. Appl Microbiol Biotechnol. 2003, 61: 413-423.View ArticlePubMed
- Liu H, Skinner M, Brownbridge M, Parker BL: Characterization of Beauveria bassiana and Metarhizium anisopliae isolates for management of tarnished plant bug, Lygus lineolaris (Hemiptera: Miridae). J Invertebr Pathol. 2003, 82: 139-147. 10.1016/S0022-2011(03)00018-1View ArticlePubMed
- Kirkland BH, Westwood GS, Keyhani NO: Pathogenicity of entomopathogenic fungi Beauveria bassiana and Metarhizium anisopliae to Ixodidae tick species Dermacentor variabilis, Rhipicephalus sanguineus, and Ixodes scapularis. J Med Entomol. 2004, 41: 705-711.View ArticlePubMed
- Lecuona RE, Edelstein JD, Berretta MF, La Rossa FR, Arcas JA: Evaluation of Beauveria bassiana (hyphomycetes) strains as potential agents for control of Triatoma infestans (Hemiptera: Reduviidae). J Med Entomol. 2001, 38: 172-179.View ArticlePubMed
- Reithinger R, Davies CR, Cadena H, Alexander B: Evaluation of the fungus Beauveria bassiana as a potential biological control agent against phlebotomine sand flies in Colombian coffee plantations. J Invertebr Pathol. 1997, 70: 131-135. 10.1006/jipa.1997.4671View ArticlePubMed
- Henke MO, De Hoog GS, Gross U, Zimmermann G, Kraemer D, Weig M: Human deep tissue infection with an entomopathogenic Beauveria species. J Clin Microbiol. 2002, 40: 2698-2702. 10.1128/JCM.40.7.2698-2702.2002PubMed CentralView ArticlePubMed
- Kisla TA, Cu-Unjieng A, Sigler L, Sugar J: Medical management of Beauveria bassiana keratitis. Cornea. 2000, 19: 405-406. 10.1097/00003226-200005000-00031View ArticlePubMed
- Beaumont F, Kauffman HF, Sluiter HJ, De Vries K: Sequential sampling of fungal air spores inside and outside the homes of mould-sensitive, asthmatic patients: a search for a relationship to obstructive reactions. Ann Allergy. 1985, 55: 740-746.PubMed
- Kurup VP, Shen HD, Banerjee B: Respiratory fungal allergy. Microbes Infect. 2000, 2: 1101-1110. 10.1016/S1286-4579(00)01264-8View ArticlePubMed
- Aukrust L: Mold allergy. Introduction. Clin Rev Allergy. 1992, 10: 147-151.PubMed
- Kurup VP, Shen HD, Vijay H: Immunobiology of fungal allergens. Int Arch Allergy Immunol. 2002, 129: 181-188. 10.1159/000066780View ArticlePubMed
- Chiu AM, Fink JN: Fungal allergy and pathogenicity. Introduction. Chem Immunol. 2002, 81: 1-4.View ArticlePubMed
- Horner WE, Helbling A, Salvaggio JE, Lehrer SB: Fungal allergens. Clin Microbiol Rev. 1995, 8: 161-179.PubMed CentralPubMed
- Banerjee B, Greenberger PA, Fink JN, Kurup VP: Immunological characterization of Asp f 2, a major allergen from Aspergillus fumigatus associated with allergic bronchopulmonary aspergillosis. Infect Immun. 1998, 66: 5175-5182.PubMed CentralPubMed
- Banerjee B, Kurup VP: Molecular biology of Aspergillus allergens. Front Biosci. 2003, 8: S128-39.View ArticlePubMed
- Kurup VP, Banerjee B, Hemmann S, Greenberger PA, Blaser K, Crameri R: Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy. 2000, 30: 988-993. 10.1046/j.1365-2222.2000.00837.xView ArticlePubMed
- Kurup VP, Banerjee B: Fungal allergens and peptide epitopes. Peptides. 2000, 21: 589-599. 10.1016/S0196-9781(00)00181-9View ArticlePubMed
- Aukrust L, Borch SM: Cross reactivity of moulds. Allergy. 1985, 40: 57-60.View ArticlePubMed
- Aalberse RC, Akkerdaas J, van Ree R: Cross-reactivity of IgE antibodies to allergens. Allergy. 2001, 56: 478-490. 10.1034/j.1398-9995.2001.056006478.xView ArticlePubMed
- Gupta R, Singh BP, Sridhara S, Gaur SN, Kumar R, Chaudhary VK, Arora N: Allergenic cross-reactivity of Curvularia lunata with other airborne fungal species. Allergy. 2002, 57: 636-640. 10.1034/j.1398-9995.2002.03331.xView ArticlePubMed
- Beaumont F, Kauffman HF, de Monchy JG, Sluiter HJ, de Vries K: Volumetric aerobiological survey of conidial fungi in the North-East Netherlands. II. Comparison of aerobiological data and skin tests with mould extracts in an asthmatic population. Allergy. 1985, 40: 181-186.View ArticlePubMed
- Beaumont F, Kauffman HF, van der Mark TH, Sluiter HJ, de Vries K: Volumetric aerobiological survey of conidial fungi in the North-East Netherlands. I. Seasonal patterns and the influence of metereological variables. Allergy. 1985, 40: 173-180.View ArticlePubMed
- Vieths S, Scheurer S, Ballmer-Weber B: Current understanding of cross-reactivity of food allergens and pollen. Ann N Y Acad Sci. 2002, 964: 47-68.View ArticlePubMed
- Weichel M, Schmid-Grendelmeier P, Fluckiger S, Breitenbach M, Blaser K, Crameri R: Nuclear transport factor 2 represents a novel cross-reactive fungal allergen. Allergy. 2003, 58: 198-206. 10.1034/j.1398-9995.2003.23822.xView ArticlePubMed
- Simon-Nobbe B, Probst G, Kajava AV, Oberkofler H, Susani M, Crameri R, Ferreira F, Ebner C, Breitenbach M: IgE-binding epitopes of enolases, a class of highly conserved fungal allergens. J Allergy Clin Immunol. 2000, 106: 887-895. 10.1067/mai.2000.110799View ArticlePubMed
- Chou H, Chang CY, Tsai JJ, Tang RB, Lee SS, Wang SR, Peng HJ, Shen HD: The prevalence of IgE antibody reactivity against the alkaline serine protease major allergen of Penicillium chrysogenum increases with the age of asthmatic patients. Ann Allergy Asthma Immunol. 2003, 90: 248-253.View ArticlePubMed
- Gupta R, Sharma V, Sridhara S, Singh BP, Arora N: Identification of serine protease as a major allergen of Curvularia lunata. Allergy. 2004, 59: 421-427. 10.1046/j.1398-9995.2003.00378.xView ArticlePubMed
- Nigam S, Ghosh PC, Sarma PU: A new glycoprotein allergen/antigen with the protease activity from Aspergillus fumigatus. Int Arch Allergy Immunol. 2003, 132: 124-131. 10.1159/000073713View ArticlePubMed
- Shen HD, Tam MF, Chou H, Han SH: The importance of serine proteinases as aeroallergens associated with asthma. Int Arch Allergy Immunol. 1999, 119: 259-264. 10.1159/000024202View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.